ArticleProstate cancer and prostatic diseases2026
Tailored use of PSA density according to multiparametric MRI index lesion location: results of a large, multi-institutional series.
Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PSA density for clinically significant prostate cancer detection: a retrospective cohort study on the influence of age and prostate volume.World journal of urology · 2026Article
- Prioritising Data Quality Governance for AI in Prostate Cancer: A Methodological Proof-of-Concept Study Using Neural Networks for Risk Stratification.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of prostate-specific antigen density (PSAd) in combination with multiparametric magnetic resonance imaging (mpMRI) of the prostate can improve accuracy of the prostate cancer (PCa) diagnostic pathway. However, it is not clear whether the performance characteristics of PSAd vary according to the index lesion location (ILL) on mpMRI.
methodsOverall, 2140 patients with positive mpMRI (prostate imaging reporting and data system [PI-RADS] ≥ 3) underwent mpMRI-targeted biopsy (TBx) plus systematic biopsy (SBx) at three tertiary referral centers. Multivariable logistic regression analysis (MVA) tested the interaction between PSAd and ILL (peripheral zone [PZ] vs transitional zone [TZ]) in predicting clinically significant PCa (csPCa, defined as ISUP grade group ≥2) at TBx. Non-parametric locally weighted scatterplots smoothing approach (LOWESS) explored the relationship between PSAd and csPCa according to ILL and stratifying by PI-RADS score.
resultsMedian PSA was 6.7 ng/ml. ILL was PZ and TZ in 77% and 23% patients, respectively. Overall, 39% of csPCa cases were diagnosed at TBx. The association between PSAd and csPCa varied according to ILL (interaction test: p < 0.01). In patients with PI-RADS 3 lesions, csPCa incidence was <10% in cases of PSAd values < 0.05 ng/ml/ml and <0.13 ng/ml/ml for PZ and TZ lesions, respectively. Differently, in patients with PI-RADS ≥ 4, csPCa incidence was ≥20% regardless of PSAd value and ILL.
conclusionsThe likelihood of detecting csPCa in patients with PI-RADS 3 lesions is influenced by the combination of PSAd and ILL. Specifically, patients with PZ and TZ PI-RADS 3 lesions have an increased risk of csPCa for PSAd values ≥ 0.05 ng/ml/ml and ≥0.13 ng/ml/ml, respectively. Conversely, patients with PI-RADS ≥ 4 lesions have a non-negligible risk of csPCa regardless of PSAd and ILL.
Indexed as
Identifiers
40456968What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.